Palatin Technologies Inc. (PTN)

[mikedeatworld]

CRANBURY, N.J., June 4, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) - Today's FDA Advisory Committee's recommendation for the approval of flibanserin is an important step forward in women's health, as the decision addresses the important need for the women living with hypoactive sexual desire disorder, or HSDD, to have an approved treatment option.

A stock owner, would know that Palatin is not developing Flibanserin. Palatin, is developing a drug called Bremelanotide.

I don't doubt, some folks may have been a tad confused. But, I think most understood the difference. In fact, the Press release later states:

Palatin Technologies is excited to continue the development of bremelanotide, a first-in-class, as needed, melanocortin-4 receptor agonist being studied for the treatment of HSDD in pre-menopausal women. Bremelanotide has a novel mechanism that activates endogenous pathways in the brain involved in creating a sexual response. It is unique because bremelanotide is an as-needed (not chronic), centrally-mediated medication. Studies have shown that it starts working within 30 to 60 minutes of administration and remains effective for approximately eight hours, providing women with greater control and flexibility in their treatment.